Drug intelligence / Profile preview

REM-949

Development stage: Preclinical
Lead developer: reMYND
Modality: Small Molecules

Overview

REM-949 is a small molecule drug in preclinical development as an inhibitor of huntingtin (HTT), the protein implicated in Huntington disease. It was initially developed by reMYND NV and is being investigated for its potential to treat neurodegenerative disorders, specifically targeting the underlying cause of Huntington disease by inhibiting the function or expression of mutant huntingtin protein[1][7].

Targets

HTT (Huntingtin protein)

Beyond the preview

Go deeper on REM-949.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REM-949.

Explore the full profile